MammoRisk® is an artificial intelligence (AI)-based tool developed by Predilife that helps doctors define the best surveillance program for women in their breast cancer surveillance. The test is dedicated for all women aged 40 or more who have never had breast cancer.

The Mammorisk® test provides a clear and accurate report for estimating the 5-year absolute risk of breast cancer. With this risk score the doctor and patient make a shared decision on a personalised monitoring program.
Mammorisk® test is done in 3 simple steps that are painless and non-invasive:

• Clinical Data Questionnaire
• Mammogram (breast density)
• Genetic Test (saliva sample)

Predilife, is a leading French company, develops predictive tests for medicine of the future: Predictive, Preventive, Personalized and Participatory (4Ps).
Predictive medicine consists of anticipating an individual’s future to act in time with customized prevention, either by reducing the risks (known as primary prevention), or by identifying the illness earlier (secondary prevention). Better prevention may be possible for serious pathologies, in particular cancers and infarction.

Mena Medical Development - MMD is the regional representative of Predilife in the Middle East and North Africa (MENA) region.